Back
Compare AU
Compare XASG vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Alphinity Global Sustainable Equity Fund - Active ETF (XASG) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
XASG | DRUG | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 68 |
Median incremental investment | $0 | $780.72 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,857.92 |
Average age group | N/A | > 35 |
Key Summary
XASG | DRUG | |
|---|---|---|
Strategy | XASG.AX was created on 2021-06-02 by Alphinity. The fund's investment portfolio concentrates primarily on total market equity. The Fund primarily invests in a diversified portfolio of leading global sustainable companies, which are aligned with one or more of the United Nations Sustainable Development Goals (SDGs), with strong ESG characteristics. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Microsoft Corp (5.54 %) Mastercard Inc Class A (5.03 %) Motorola Solutions Inc (4.65 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Information Technology (50.71 %) Financials (18.80 %) Health Care (15.55 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0.75 % | 0.57 % |
Key Summary
XASG | DRUG | |
|---|---|---|
Issuer | Alphinity | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.75 % | 0.57 % |
Price | $6.90 | $7.80 |
Size | N/A | $159.646 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 2.51 % | 1.97 % |
Market | ASX | ASX |
First listed date | 16/01/2023 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
XASG | DRUG | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 68 |
Median incremental investment | $0 | $780.72 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,857.92 |
Average age group | N/A | > 35 |
Pros and Cons
XASG | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
XASG | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |